Drug Trial News

RSS
Drug treatment reduces gout flares in clinical study

Drug treatment reduces gout flares in clinical study

Study sheds light on the mechanism of lung damage in premature babies

Study sheds light on the mechanism of lung damage in premature babies

Study: Breast cancer clinical trials fail to establish control arm that meets current standard of care

Study: Breast cancer clinical trials fail to establish control arm that meets current standard of care

Trial identifies genetic fault that affects treatment response in leukemia patients

Trial identifies genetic fault that affects treatment response in leukemia patients

Study shows benefits of delayed-release stimulant in children with ADHD

Study shows benefits of delayed-release stimulant in children with ADHD

Trial shows safety and tolerability of antisense oligomer for treatment of influenza A

Trial shows safety and tolerability of antisense oligomer for treatment of influenza A

Combination treatment improves progression-free survival in patients with advanced urothelial cancer

Combination treatment improves progression-free survival in patients with advanced urothelial cancer

Study: New oral drug helps control glucose, reduces need for insulin in patients with type 1 diabetes

Study: New oral drug helps control glucose, reduces need for insulin in patients with type 1 diabetes

Insmed reports top-line data from Phase 3 study of new treatment in patients with NTM lung disease

Insmed reports top-line data from Phase 3 study of new treatment in patients with NTM lung disease

Tulane University researchers develop new drug effective against malaria

Tulane University researchers develop new drug effective against malaria

New medication shows potential to reduce fracture risk in women with osteoporosis

New medication shows potential to reduce fracture risk in women with osteoporosis

Antibody therapy found effective in subgroup of patients with treatment-resistant COPD

Antibody therapy found effective in subgroup of patients with treatment-resistant COPD

Australian researchers make ultimate move in the battle against melanoma

Australian researchers make ultimate move in the battle against melanoma

Combination therapy found to be effective adjuvant treatment option in melanoma patients

Combination therapy found to be effective adjuvant treatment option in melanoma patients

Combination immunotherapy as second or third line treatment of mesothelioma shows promising results

Combination immunotherapy as second or third line treatment of mesothelioma shows promising results

Study: Maintenance therapy increases progression-free survival in BRCA mutant recurrent ovarian cancer

Study: Maintenance therapy increases progression-free survival in BRCA mutant recurrent ovarian cancer

Study: Immunotherapy shows promising response rate in patients with metastatic gastric cancer

Study: Immunotherapy shows promising response rate in patients with metastatic gastric cancer

Two new treatments may benefit patients with high risk prostate cancer, trial shows

Two new treatments may benefit patients with high risk prostate cancer, trial shows

New trial confirms superiority of triplet regimen over standard care in resectable esophago-gastric cancer

New trial confirms superiority of triplet regimen over standard care in resectable esophago-gastric cancer

LORELEI trial: Treatment with alpha specific PI3K inhibitor reduces breast tumor size

LORELEI trial: Treatment with alpha specific PI3K inhibitor reduces breast tumor size

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.